Last Updated : March 12, 2025
Details
Generic Name:
asciminib
Project Status:
Received
Therapeutic Area:
Philadelphia chromosome-positive chronic myeloid leukemia
Manufacturer:
Novartis Pharmaceuticals Canada
Call for patient/clinician input open:
Brand Name:
Scemblix
Project Line:
Reimbursement Review
Project Number:
PC0405-000
Call for patient/clinician input closed:
Tumour Type:
Leukemia
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with newly diagnosed or previously
treated Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in
chronic phase (CP).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the treatment of adult patients with newly diagnosed or previously treated Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 30-Jan-25 |
|---|---|
| Call for patient/clinician input closed | 24-Mar-25 |
| Submission received | 10-Mar-25 |
| Submission accepted | - |
Last Updated : March 12, 2025